Please assess the completion status of the following clinical trial:

Trial Title: Study of KCC Peptide Application in the Colon

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects felt to be at increased risk for CRC and colonic polyps~OR~-Subjects with known colonic adenomas scheduled for colonic resection~OR~* Subjects who are scheduled for outpatient colonoscopy for follow up surveillance of IBD with known dysplasia or who are at high risk for high grade dysplasia.~* Subjects who are scheduled for outpatient colonoscopy in the medical procedures unit at the University of Michigan Health Center~* All subjects who are medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) who meet the inclusion/exclusion criteria will be included. Standard practice guidelines for safely proceeding with the procedure will be sufficient for our study~* Adults aged 18 to 100 years~* Willing and able to sign informed consent~* The effects of Colon KCC Heptapeptide (5-FITC-labeled peptide) on the developing human fetus are unknown. For this reason, women of childbearing potential must have a negative pregnancy test on the day of the procedure prior to receiving the Colon KCC Heptapeptide (5-FITC-labeled peptide agent) or be post-menopausal. Post-menopausal women are defined as post-hysterectomy, or over 40 and at least 18 months without menses and not on birth-control.~Exclusion Criteria:~* Subjects with known allergy or negative reaction to fluorescein or derivatives.~* Subjects on active chemotherapy or radiation treatment~* Pregnant or trying to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- peptide application (Type: EXPERIMENTAL): Investigational Agent Administration~* KCCFPAQ-GGGSK-(5-FITC)-NH2~* 1.2 mg lyophilized powder per single-use amber vial~* Lyophilized powder reconstituted with 10 mL of 0.9% NaCl~* Final concentration of 76.4 μM for single, one-time topical application~* The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)

Based on this trial design, predict the completion outcome and termination type (if applicable).